Evaluation of Adverse Drug Reactions (ADRs) in Breast Cancer Patients Who Received Doxorubicin, Cyclophosphamide (AC) and Doxorubicin, Cyclophosphamide, Paclitaxel (AC-T) Chemotherapy at West Nusa Tenggara Provincial Hospital
Downloads
Background: Chemotherapy is commonly used to treat breast cancer (BC). Chemotherapy may cause ADRs in patients, affecting their physical and psychological wellbeing. Objective: To understand the adverse drug reaction (ADR) profile in patients with breast cancer who received AC-T and AC chemotherapy at the West Nusa Tenggara Provincial Hospital. Methods: This observational study used cross-sectional data collected from medical records and direct interviews with the patients between May and June. Probability categories were measured using the Naranjo algorithm questionnaire, causality categories were measured using a causality flowchart, and the severity level of ADRs was determined using the Common Terminology Criteria for Adverse Events (CTCAE) 5.0. Results: The probability results for the AC-T regimen were as follows: possible (10 %), probable (54.44 %), and definite (35.56 %). whereas The AC regimen showed categories of possible (6.67%), probable (63.33%), and definite (30%). The causality results for the AC-T regimen were categorized as unlikely (1.11%), possible (12.22%), probable (25.56%), or certain (61.11%), whereas those for the AC regimen were categorized as possible (6.67%), probable (43.33%), or certain (50%). The most common ADRs were alopecia and nausea, with the highest probability in the probable category for AC-T (54.44%) and AC (63.33%), respectively. Conclusion: Respondents who received the AC-T regimen experienced more severe ADRs in terms of hematologic disorders (anemia, leukopenia, and thrombocytopenia) and symptoms of nausea, pain, and fever than those who received the AC regimen.
Balai Pengawasan Obat dan Makanan Republik Indonesia. (2020), Modul Farmakovigilans Dasar, Project for Ensuring Drug and Food Safety. Jakarta, Project for Ensuring Drug and Food Safety :BPOM, Jakarta.
Basuki, A.R., Perwitasari, D.A. and Hardiyanto, H. (2020), “Adverse Drug Reactions (ADRS) Antikanker pada Pasien Ca Mammae yang Menjalani Kemoterapi di RSUD Kota Yogyakarta”, Jurnal Health Sains, Vol. 1 No. 6, pp. 349–359.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018), "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA: A Cancer Journal for Clinicians, Wiley Online Library, Vol. 68 No. 6, pp. 394–424.
Effendi, J.A.J. and Anggun, N. (2019), “Studi Efek Samping Penggunaan Obat Kemoterapi Pasien Kanker Payudara (Carcinoma Mammae) di RSUD Kraton Pekalongan”, Pena Medika Jurnal Kesehatan, Vol. 9 No. 2, pp. 48–54.
Hidayatullah, M.T. (2015), Profil Adverse Drug Reactions Cisplatin Regimen Kemoterapi Pada Pasien Kanker Servik Di RSUD Prof. Dr. Margono Soekardjo Purwokerto, Universitas Muhammadiyah Purwokerto, Purwokerto.
Hilli, Y.W. (2017), “Hubungan Karakteristik dan Frekuensi Kemoterapi dengan Tingkat Gangguan Fisik (Alopesia, Nausea dan Vomit) pada Pasien Kanker yang Menjalani Kemoterapi di Ruangan Mutis RSUD Prof. Dr. WZ Johannes Kupang”, CHMK Nursing Scientific Journal, Vol. 1 No. 2.
Kang, Y.-K., Si, Y.-R., An, G.-Y. and Yuan, P. (2021), "Efficacy and safety of cyclophosphamide in anthracycline-and taxane-based neoadjuvant chemotherapy in breast cancer: a meta-analysis", Gland Surgery, Vol. 10 No. 1, p. 252.
Khairani, S., Keban, S.A., and Afrianty, M. (2019), "Evaluation of drug side effects chemotherapy on quality of life (QOL) breast cancer patients at hospital x in Jakarta", Jurnal Ilmu Kefarmasian Indonesia, Vol. 17 No. 1, pp. 9–13.
Kim, G.M., Kim, J.H., Kim, J.H., Cho, Y.U., Kim, S. Il, Park, S., Park, H.S., et al. (2019), "A phase II study to evaluate the safety and efficacy of pegteograstim in Korean breast cancer patients receiving dose-dense doxorubicin/cyclophosphamide", Cancer Research and Treatment: Official Journal of Korean Cancer AssociationVol. 51 No. 2, pp. 812–818.
National Cancer Institute. (2017), Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Oh, H.-J.S., Menéndez, Á.F., Santos, V.S., Martínez, Á.R., Ribeiro, F.F., Vilanova-Trillo, L., Figueiras, M.C., et al. (2021), "Evaluating health related quality of life in outpatients receiving anticancer treatment: results from an observational, cross-sectional study", Health and Quality of Life Outcomes, Vol. 19 No. 1, pp. 1–8.
Pangribowo, S. (2019), “Beban Kanker di Indonesia”, Pusat Data Dan Informasi Kesehatan Kementerian Kesehatan RI, pp. 1–16.
Piepoli, M.F., Hoes, A.W., Agewall, S., Albus, C., Brotons, C., Catapano, A.L., Cooney, M.-T., et al. (2016), "2016 European Guidelines on cardiovascular disease prevention in clinical practice", Kardiologia Polska (Polish Heart Journal), Vol. 74 No. 9, pp. 821–936.
Prieto-Callejero, B., Rivera, F., Fagundo-Rivera, J., Romero, A., Romero-Martín, M., Gómez-Salgado, J. and Ruiz-Frutos, C. (2020), "Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer", Medicine, Vol. 99 No. 33.
Ratna, R., Supadmi, W. and Yuniarti, E. (2021), “Kualitas Hidup Pasien Kanker Rawat Jalan yang Menjalani Kemoterapi di RSUD Kota Yogyakarta”, Majalah Farmaseutik, Vol. 17 No. 2, pp. 278–286.
Sukandar, E.Y., Hartini, S. and Rizkita, P. (2014), “Evaluasi Reaksi Obat Merugikan pada Pasien Kemoterapi Kanker Payudara di Salah Satu Rumah Sakit di Bandung (Evaluation of Adverse Effects in Patient with Breast Cancer Chemotherapy at A Hospital in Bandung)”, Jurnal Ilmu Kefarmasian Indonesia, Vol. 12 No. 2, pp. 183–192.
Syamsuddin, S., Tahir, M.Y. and Plasay, M. (2020), “Hubungan Efek Samping Kemoterapi Dengan Kualitas Hidup Pasien Kanker Payudara di Rumah Sakit Ibnu Sina Makasar”, J. Keperawatan.
Wahyuni, R.S. (2021), “Hubungan Pengetahuan dan Tindakan Terhadap Deteksi Dini Kanker Payudara Pada Remaja Putri di SMAN 10 Pekanbaru”, Jurnal Kesehatan Medika Udayana, Vol. 7 No. 02, pp. 104–113.
Wicaksono, A.W. (2022), Analisis Adverse Drug Reactions (Adrs) Dan Penanganannya Pada Pasien Kanker Payudara Dengan Regimen Paclitaxel-Epirubicindi RSUD Dr. Moewardi Surakarta, Universitas Muhammadiyah Surakarta, Surakarta.
Wongkar, R., Angka, R.N. and Angeline, R. (2022), “Karakteristik Pasien Kanker Stadium 4 yang Mendapatkan Perawatan Paliatif di Rumah Sakit X”, Jurnal Kedokteran Meditek, Vol. 28 No. 2, pp. 126–132.
Yuniarti, E., Supadmi, W., Wahyuni, F.A. and Ratna, R. (2021), “Kualitas Hidup Pasien Kanker yang Menjalani Kemoterapi di Rumah Sakit Yogyakarta”, Prosiding University Research Colloquium, pp. 594–606.
Copyright (c) 2024 JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
1. The copyright of this journal belongs to the Editorial Board and Journal Manager with the author's knowledge, while the moral right of the publication belong to the author.
2. The formal legal aspect of journal publication accessibility refers to the Creative Commons Attribution-Non-Commercial-Share Alike (CC BY-NC-SA), which implies that the publication can be used for non-commercial purposes in its original form.
3. Every publication (print/electronic) is open access for educational, research, and library purposes. In addition to the objectives mentioned above, the editorial board is not responsible for copyright infringement
.jpg)
